Introduction
Hypoxia has been shown to exert immunomodulatory effects 1 . As oxygenation is daily practice in critical care, and the majority of critically ill patients suffer from inflammatory-related conditions, permissive hypoxia might be a novel therapeutic strategy. In addition, there are pharmacologic hypoxia-mimetics available that can replicate the hypoxia-effects without the potential drawbacks of systemic hypoxia. The hypoxic immunomodulatory effects are thought to be mediated through a group of transcription factors called hypoxia-inducible factors (HIFs) 2 . However, in vitro studies have demonstrated that, depending on the cell-type, these effects can be both pro-and anti-inflammatory. The net effects of hypoxia during systemic inflammation in vivo are therefore unknown.
Objectives
To determine the immunomodulatory effects of various degrees of hypoxia and hypoxia mimetics during systemic inflammation in mice.
Methods
BALB/c mice (n = 8 per group) were placed in an air-tight cage with variable degrees of oxygen (normal (21%), 12%, 9%, and 6%), or were injected with the hypoxia-mimetic cobalt chloride (CoCl 2, 30mg/kg i.p.). After 1 hour, LPS (5 mg/kg E. Coli endotoxin, serotype 0111:B4) or placebo (NaCl 0.9%) was administered i.p. Ninety minutes after LPS/placebo administration, rectal temperature was measured and animals were sacrificed. Blood plasma was analyzed for cytokine concentrations. Furthermore, mRNA expression of interleukin (IL)-10 and the HIF-1α target gene vascular endothelial growth factor (VEGF) were determined in spleen samples.
Results
As expected, LPS administration resulted in hypothermia. Hypoxia and CoCl 2 also lowered body temperature, in a dose-dependent fashion (Figure 1 manner, while IL-10 protein levels were relatively unaffected. Furthermore, hypoxia resulted in a dosedependent upregulation of splenic VEGF and IL-10 mRNA expression (Figure 3 ).
Conclusions
Hypoxia results in hypothermia and attenuation of the systemic pro-inflammatory response in a dose-dependent fashion, while preserving or enhancing the anti-inflammatory response. Administration of the hypoxia-mimetic CoCl 2 results in a similar immunological phenotype. Our results suggest that permissive hypoxia is a novel nonpharmacological anti-inflammatory therapeutic strategy. 
